Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • About Our Firm
  • Free Case Evaluation
  • Frequently Asked Questions

Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma

March 14, 2022 By Law Offices of Thomas J. Lamb, P.A.

[ Verzenio (abemaciclib), a drug that has proven effective in breast cancer, ] showed preliminary activity in its first-ever clinical trial in mesothelioma. The cyclin-dependent kinase (CDK) 4/6 inhibitor [ Verzenio (abemaciclib) ] achieved disease control at 12 weeks in 14 of 26 patients with progressive mesothelioma associated with a CDKN2A … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

February 22, 2022 By Law Offices of Thomas J. Lamb, P.A.

Background: In the phase 3 CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma [(unresectable MPM)]. We report updated data with 3-year minimum follow-up. Patients and methods: Adults with previously … [Read more...]

Filed Under: Mesothelioma Tagged With: ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, nivolumab

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

February 15, 2022 By Law Offices of Thomas J. Lamb, P.A.

Introduction:  Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. This study reviewed the Dutch population-based incidence, treatment and survival since the national ban on asbestos in 1993. Materials and methods:  Patients with MPM or MPeM … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma diagnosis, mesothelioma treatments, peritoneal mesothelioma

Malignant pleural mesothelioma patients’ experience by gender: findings from a cross-sectional UK-national questionnaire

February 2, 2022 By Law Offices of Thomas J. Lamb, P.A.

OBJECTIVES: Malignant mesothelioma is an aggressive malignancy of mesothelial surfaces, most commonly those of the pleura. The aim of this study was to understand, using a national questionnaire, the gendered care experiences of patients with malignant pleural mesothelioma (MPM). Patients were asked about their experience of the diagnostic process, … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma diagnosis, mesothelioma treatments

Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma

January 13, 2022 By Law Offices of Thomas J. Lamb, P.A.

We compared less invasive surgery with conventional surgery for malignant pleural mesothelioma (MPM). We retrospectively reviewed consecutive patients with MPM who received surgery at Hyogo College of Medicine between July 2004 and April 2016. Patients underwent multimodal treatment comprising chemotherapy (neoadjuvant and/or adjuvant) and surgery … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, pneumonectomy

Immune Checkpoint Inhibitors Extend Survival for Mesothelioma

December 30, 2021 By Law Offices of Thomas J. Lamb, P.A.

Immune checkpoint inhibitor (ICI) therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma (MPM), offering more effective and less toxic treatment options for patients. The research and clinical oncology communities eagerly await the completion of several upcoming trials focused on … [Read more...]

Filed Under: Mesothelioma Tagged With: Immune checkpoint inhibitor, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma

December 16, 2021 By Law Offices of Thomas J. Lamb, P.A.

Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer. The open-label, multicenter CheckMate-743 trial included 605 patients who received six cycles of pemetrexed and … [Read more...]

Filed Under: Mesothelioma Tagged With: ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma treatments, nivolumab, Opdivo, Yervoy

Imfinzi-Chemo Combo Improves Survival for Mesothelioma

November 22, 2021 By Law Offices of Thomas J. Lamb, P.A.

Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone. Treatment with Imfinzi (durvalumab) plus platinum-pemetrexed chemotherapy was associated with improved survival among patients with previously untreated, … [Read more...]

Filed Under: Mesothelioma Tagged With: Imfinzi, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, platinum-pemetrexed chemotherapy

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

November 4, 2021 By Law Offices of Thomas J. Lamb, P.A.

Background:  No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab [(Opdivo)], an anti-PD-1 antibody, in these patients. Methods:  This was a multicentre, … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments, Opdivo, peritoneal mesothelioma

Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma

October 29, 2021 By Law Offices of Thomas J. Lamb, P.A.

The combination of [ Opdivo and Yervoy ] maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results. Researchers observed the benefit of the first-line immunotherapy regimen despite patients having been off … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • Philips Breathing Devices Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2022 · Law Offices of Thomas J. Lamb, P.A.